Outset Medical Reports Q3 Revenue of $29.4 Million

Reuters11-11

Outset Medical Reports Q3 Revenue of $29.4 Million

Outset Medical Inc. reported third-quarter 2025 net revenue of $29.4 million, an increase of 3.0% from the same period last year, driven by an 8.0% rise in Tablo console revenue. Recurring revenue from Tablo consumables and services reached $21.1 million, showing a slight increase from the prior year period. Gross margin was 39.4%, with a non-GAAP gross margin of 39.9%, up 3.5 percentage points year-over-year. Operating expenses declined nearly 20% compared to the third quarter of 2024, and the company used less than $6.0 million in cash during the quarter, ending with approximately $182 million in cash and short-term investments. Outset Medical revised its 2025 revenue outlook to $115-$120 million, down from a previous range of $122-$126 million, while maintaining its non-GAAP gross margin guidance in the high-30% range. The company expects to use less than $50 million in cash for 2025, compared to over $100 million used in 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outset Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572616-en) on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582800836?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582800836","market":"us","top_or_hot":-1,"title":"Outset Medical Reports Q3 Revenue of $29.4 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Outset Medical Reports Q3 Revenue of $29.4 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/OM\">Outset Medical Inc.</a> reported third-quarter 2025 net revenue of $29.4 million, an increase of 3.0% from the same period last year, driven by an 8.0% rise in Tablo console revenue. Recurring revenue from Tablo consumables and services reached $21.1 million, showing a slight increase from the prior year period. Gross margin was 39.4%, with a non-GAAP gross margin of 39.9%, up 3.5 percentage points year-over-year. Operating expenses declined nearly 20% compared to the third quarter of 2024, and the company used less than $6.0 million in cash during the quarter, ending with approximately $182 million in cash and short-term investments. Outset Medical revised its 2025 revenue outlook to $115-$120 million, down from a previous range of $122-$126 million, while maintaining its non-GAAP gross margin guidance in the high-30% range. The company expects to use less than $50 million in cash for 2025, compared to over $100 million used in 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outset Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572616-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Outset Medical Reports Q3 Revenue of $29.4 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOutset Medical Reports Q3 Revenue of $29.4 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Outset Medical Reports Q3 Revenue of $29.4 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/OM\">Outset Medical Inc.</a> reported third-quarter 2025 net revenue of $29.4 million, an increase of 3.0% from the same period last year, driven by an 8.0% rise in Tablo console revenue. Recurring revenue from Tablo consumables and services reached $21.1 million, showing a slight increase from the prior year period. Gross margin was 39.4%, with a non-GAAP gross margin of 39.9%, up 3.5 percentage points year-over-year. Operating expenses declined nearly 20% compared to the third quarter of 2024, and the company used less than $6.0 million in cash during the quarter, ending with approximately $182 million in cash and short-term investments. Outset Medical revised its 2025 revenue outlook to $115-$120 million, down from a previous range of $122-$126 million, while maintaining its non-GAAP gross margin guidance in the high-30% range. The company expects to use less than $50 million in cash for 2025, compared to over $100 million used in 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outset Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572616-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLHgt2X:1","article_id":"2582800836","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582800836","pubTimestamp":1762808747,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Outset Medical Inc. reported third-quarter 2025 net revenue of $29.4 million, an increase of 3.0% from the same period last year, driven by an 8.0% rise in Tablo console revenue. Recurring revenue from Tablo consumables and services reached $21.1 million, showing a slight increase from the prior year period. Gross margin was 39.4%, with a non-GAAP gross margin of 39.9%, up 3.5 percentage points year-over-year. Operating expenses declined nearly 20% compared to the third quarter of 2024, and the company used less than $6.0 million in cash during the quarter, ending with approximately $182 million in cash and short-term investments. Outset Medical revised its 2025 revenue outlook to $115-$120 million, down from a previous range of $122-$126 million, while maintaining its non-GAAP gross margin guidance in the high-30% range. The company expects to use less than $50 million in cash for 2025, compared to over $100 million used in 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","OM":"Outset Medical Inc."},"translate_title":"Outset Medical报告第三季度收入为2940万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OM":0.9},"content_text":"Outset Medical Reports Q3 Revenue of $29.4 Million\n    \n\nOutset Medical Inc. reported third-quarter 2025 net revenue of $29.4 million, an increase of 3.0% from the same period last year, driven by an 8.0% rise in Tablo console revenue. Recurring revenue from Tablo consumables and services reached $21.1 million, showing a slight increase from the prior year period. Gross margin was 39.4%, with a non-GAAP gross margin of 39.9%, up 3.5 percentage points year-over-year. Operating expenses declined nearly 20% compared to the third quarter of 2024, and the company used less than $6.0 million in cash during the quarter, ending with approximately $182 million in cash and short-term investments. Outset Medical revised its 2025 revenue outlook to $115-$120 million, down from a previous range of $122-$126 million, while maintaining its non-GAAP gross margin guidance in the high-30% range. The company expects to use less than $50 million in cash for 2025, compared to over $100 million used in 2024.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outset Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572616-en) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582800836","isCrawlerRequest":true}